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ABSTRACT
The human immune system is critical for
maintaining health and providing protection from
infectious diseases and cancer. Major advances in
our understanding of the immune system have
largely emerged from studies using animal models
such as mice. However, this mouse-centric research
has also limited our ability to comprehend the
human immune system and how it changes with
age and disease state. The fact that we have yet to
define what constitutes a normal human immune
system has hampered our ability to diagnose, treat,
and prevent many human diseases. Immunoprofiling
that measures the frequency of human immune
cells based upon their functional biomarkers is
critical for immunotherapy. With major advances
in flow cytometry, mass cytometry, and imaging
technology it is now possible to rapidly characterize
many types of immune cells for immunotherapy
and for monitoring disease. In this article, we
discuss recent progress in immunoprofiling of the
human immune system and how this system changes
with age, chronic diseases, and autoimmunity. We
also discuss this in the historical context as it
relates to the emergence of human immunology.
New knowledge generated by immunoprofiling
studies will allow better understanding and
monitoring of immune cells and their application
in clinical medicine.
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1. Introduction
The human immune system is a complex network
of cells and proteins that are highly interactive,
diverse, and adaptive. Humans have over 100
immune cell types that are phenotypically highly
stable within an individual but variable between
individuals [1, 2]. This variability in frequency
and functional responses of immune cells is due
to genetic polymorphism and to the fact that the
composition of the immune system is largely
determined by non-genetic environmental factors,
which can vary substantially from one individual
to another [3]. Given its complex nature, it is
difficult to define standard baseline values for the
components of the normal immune system and
how it changes with the long list of endogenous
conditions (including genetics, sex, age, inflammation,
microbiome and autoimmunity) and exogenous
factors with which it interacts (such as infectious
agents, diet, allergens, transplants and medications)
[4-10].
Immunoprofiling is a measure of the state of the
immune system at a given time point. It provides
a window into what immune cell types predict,
induce, promote or prevent disease, and how the
immune system responds to infections, vaccines,
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or immunotherapy. As such, it contributes to our
understanding of certain immunological baselines
for it can be used to measure the impact of various
therapies and the environmental influences on
the immune system. Immunoprofiling of blood
leukocytes provides a powerful tool for the
monitoring of immune cells in vivo [11]. Monitoring
of CD4+ T cell counts has been the hallmark of
disease progression and therapy in HIV infected
patients over the past three decades. What these
activities have shown is that, in general, immune
responses are driven by interactions between
different immune cell types having stimulatory or
suppressive proprieties. Immunoprofiling offers
an opportunity to better understand these dynamic
cellular interactions at a functional level. The
development of immunoprofiling has been
importantly powered by new technologies, such as
flow cytometry, mass cytometry, cellular and
molecular imaging, and the analysis of large data
sets of genomics, proteomics and metabolomics
studies that have added new understanding of the
nature of immune cells. This has also contributed
to a better tracking of pathogenic cells and
immune cells in vivo and improved assessment of
human immune function and clinical outcomes
during immunotherapy [12, 13]. The area of
human immunoprofiling is thus emerging from
the recent developments in systems biology and
human immunology [14]. It has provided new
direction to the application of immunology in
clinical medicine, the most noteworthy being
cancer immunotherapy. This is likely to impact
the discovery of new immunological mechanisms
involving cell-cell interactions, cell signaling and
the elucidation of genetic and environmental
influences in human health. At the molecular
level, immunoprofiling can be used to measure
the diversity of immune responses based on
antigen receptor specificity. Next generation
sequencing of DNA allows profiling of antigen
receptors on B cells and T cells and this can be
used in turn to determine how the diversity of the
receptors changes during immune response to
antigens, allergens, infections, vaccines or transplants
[15]. This has potential to develop genetic
biomarkers for comparing baseline immune
diversity and how it changes during disease or
therapy. In cancer immunotherapy immunoprofiling
is being used to develop biomarkers that can be

used to monitor treatments and detect remissions
at an early stage. Therefore, immunoprofiling
can be used at the molecular level to understand
how immune cells target cancer cells and how
immunotherapy helps in this process.
While technological advancements provided new
research opportunities, any discussion of the
clinical application of immunoprofiling will be
incomplete without the historical and philosophical
context of the emergence of human immunology
[12, 14, 16, 17]. In the last century, the discovery of
the complex adaptive nature of the immune system
helped to motivate a shift in perspective that raised
a number of issues with research that focused
overwhelmingly on animal models, particularly
genetically modified inbred mouse models.
Significant differences exist between the human
immune system and that of experimental mouse
models, which have limited the translation of
these studies to humans. Because of this shift, the
technological developments mentioned above, and
the recent elucidation of the human genome, human
immunology is now embracing new opportunities
that may lead to the improved translation of
research results into clinical outcomes. In this
article we discuss the recent progress in the field
of immune profiling and focus on the characterization
of immune cells through immunophenotyping
during the course of disease or in response to
therapy. These studies will also help to define
what constitutes a healthy or normal immune
system, and serve as a clinical benchmark to
assess immune changes with age, disease state
and treatment.
2. Human immunology – a developmental history
The field of human immunology has taken a leap
forward in the past decade after being overshadowed
by studies predominantly performed in mouse
models of immunity over the past century. Both
conceptual and technological advances have made
this possible and we now have potential to better
understand the immunological mechanisms and
treatment of many human diseases given the
genetic diversity and environmental influences in
human populations.
In the mid-18th century, immunology evolved as
the study of mechanisms of protection against
infection—mechanisms of immunity—with the
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development of inoculation and vaccination as
measures for preventing smallpox. The realization
that an infectious disease could be prevented by
such methods inaugurated a program of research
that culminated with the work of Louis Pasteur
and the generation of vaccines for many infectious
diseases including fowl cholera, anthrax, and
rabies. This early research, with its close
connection to clinical practice, was followed by
a period of intense basic research along two
different but complementary lines: cellular
components and molecular units, both probing the
mechanisms underlying immune function. Indeed,
the recent interest in human immunology suggests
that immunology is returning to its historical and
clinical roots.
For much of the last 50 years, immunology has
focused on achieving a comprehensive mechanistic
understanding of the molecular basis of immunity,
aided by technological advances such as recombinant
DNA and the application of molecular biology
in developing and characterizing novel in vitro
and in vivo models of immune function. Indeed,
success in identifying molecular and cellular
mechanisms of immunity has given immunology
a high profile within medicine, offering potential
mechanistic explanations for particular diseases
and suggesting possibilities for therapeutic
intervention and vaccine development. As a result,
the discipline has grown beyond its descriptive
focus of immunity [18] and now encompasses the
study of disorders resulting from the loss of
immune protection (e.g., primary and secondary
immunodeficiency states), disorders associated
with abnormal targeting of such mechanisms
(e.g., allergy and autoimmune diseases), and
therapeutic modulation of immune mechanisms
(e.g., transplantation immunology and cancer
immunotherapy). With this extended framework,
immunology now reaches across disciplinary
boundaries, demanding the integration of multiple
disciplines including cell biology, biochemistry,
anatomy, genetics, developmental biology,
microbiology and infectious diseases, and
epidemiology.

background suggests that the immune system is a
Complex Adaptive System (CAS) without an
overall master regulator. It is not a simple aggregate
of the properties of the immune systems’ components
taken in isolation, but the result of complex and
ongoing interactions between organisms and their
environments. The immune system has emerged
from the interactions among a large number of
tightly integrated components in such a way as
to enable the system to respond flexibly to a
changing environment. In general, the immunity
is modified in response to environmental stimuli
of a different sort: the properties of certain kinds
of molecules and antigens (e.g. vaccines) to which
the organism is exposed via its immune receptors
[19-21]. Ultimately, the primary selective pressure
favouring the development of immunity is the
need to resist infection [22].
Accumulating evidence shows that the history of
antigen exposure, including exposure to microbiota
residing in or on body sites, systematically shapes
the development and function of an individual’s
immune system. Although immunological memory
remains poorly understood at the cellular and
molecular levels, some of its functional repercussions
are well documented. We know for example that
the immune system constantly builds a pool of
memory lymphocytes based on microbial exposure
and on immune interventions such as vaccines.
Since the capacity of an organism to respond to
pathogens depends on the repertoire of clones
able to respond to antigens derived from those
pathogens, the immune response depends on an
individual's history of pathogen exposure. Thus,
the physiology of an immune system depends
not only on the present environment that it inhabits,
but also on its history — both its individual
developmental history and the evolutionary
history of the population that it belongs to [23].
A further challenge to human immunology research
results from the dynamic character of a CAS as
it responds to a changing environment. The
importance of both individual and evolutionary
history of immune function implies primacy for
the study of human immune systems in vivo.

3. Complexity of the human immune system

4. Normal human immune system

Exploration of the conceptual landscape of
immunology, its history, and its biological

In light of the immune system’s complex adaptive
structure, it is important to develop conceptual
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and investigative tools for studying the dynamic
nature of the intact human immune system in its
natural environment. In this context immunoprofiling
offers a valuable tool to define the normal and an
altered immune system and what “normal” should
mean in the context of an immune system [16]. As
Georges Canguilhem argued [24], the concepts of
normality and pathology are essential to medicine
and can be comprehended only in its context. The
task of defining normality in a system such as the
immune system is particularly challenging given
its dynamic nature and the biological, social and
environmental factors that may alter the status of
an apparently normal or otherwise “healthy” immune
system. Yet providing a precise specification of
the normal immune system is an important step
towards the definition of immune health determinants.
We need to understand two basic questions about
the human immune system. First, what is a normal
human immune system and how does it develop
and decline with age? Second, how do disease
states impact the immune system? Answer to
these questions are prolegomena to expanding the
horizon of the human immunology research and
enhancing its impact on medical practice [25-27].
We believe that this can be done in a way
analogous to the identification of individual and
social risk factors. The complex adaptive structure
of the immune system implies that what counts as
normal will change from one environment to
another, and indeed from one life-history to
another even within the same environment. Thus,
multiple alternative normal states for the immune
system may be possible, depending on the
environments (natural and cultural) in which it
develops. In light of this historical and context
sensitivity, we define a normal immune system as
one that provides adequate immunity for a specific
environment. This definition has important
empirical and clinical ramifications. If we accept
that what is “normal” should be determined by
what is “adequate for the organism’s health”, then
the induction of immune responses by vaccination
or the presence of ongoing immune responses to
environmental antigens or certain microbes should
be viewed as compatible with normality. Our
definition encompasses exposure to pathogens as
a requirement for normal development of the
immune system or to build normal immunity to
minor frequent infections such as chickenpox and

the common cold. Another implication of our
definition is that one can discover different
manifestations of immune system normality in a
given context if there are diverse, yet adequate,
responses to a given stimulus.
5. Immunoprofiling and human health
Immunoprofiling of cells in the normal immune
system and their alteration during the course of
disease progression or clinical treatment has
become a cornerstone of immunotherapy. The
selective use of biomarkers to simultaneously and
rapidly measure distinct immune cell populations
is critical for immunophenotyping and its
application to disease monitoring and patient care
[28, 29]. In this context we discuss the use of
immunoprofiling in several health-related areas
such as vaccination, aging, autoimmunity and
chronic inflammatory diseases.
5.1. Immunophenotypic readout of immune
responses to vaccination

In the last few years immune profiling has been
successfully used in tracking immune responses in
humans using systems biology approaches [17].
Using this approach, researchers have been able to
identify early immune biomarkers that predict
successful immune responses in humans vaccinated
with the yellow fever vaccine [30], and provided
correlates of successful vaccination with over
90% accuracy, thus measuring early vaccine
efficiency. These studies have pointed to the
development of rapid tests for determining whether a
person can respond effectively to a vaccine and
define the utility of phenotyping of immune cells
in predicting vaccine efficacy [31, 32].
5.2. Age-related immunophenotypic changes

It is known that aging humans undergo dramatic
changes in their immune system along with an
increased susceptibility to infections and chronic
diseases including cancer. Conventional approaches
have identified several underlying factors such as
reduced CD8+ T cells and impaired dendritic cell
function in the elderly. Similar changes are
observed in patients with chronic diseases and
cancer. However, given the diversity of the human
population it is necessary to develop more
universally applicable biomarkers that can be used
to monitor the immune system and correlate to
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disease risk. Immunoprofiling thus becomes an
important platform for monitoring the age-related
changes that occur in the human immune system
[33]. Immunoprofiling done over 9 years in a
human cohort gave an immune aging (IMM-AGE)
score based on 33 cellular subsets, including
CD8+ T cell, monocytes, natural killer (NK) cells,
B cells, and CD4+ T cell subsets. [34]. This score,
which enables tracking immune age in real time,
was related to genetics, environmental and previous
exposure to pathogens. Similarly, individual cytokine
response was more significantly associated with
the IMM-AGE score than with actual age of the
subjects. This study suggests that the immune
cell variation between individuals was greater
than that within an individual over time. The
high inter-individual immune cell variability is
dependent on their baseline value. Moreover,
there was significant immune-system dynamics in
older subjects as compared to its stability in the
younger subjects. It appears that immune cell
homeostasis of young and older adults differs but
over time they converge and move towards the
adult phenotype as defined by an increased pool
of memory lymphocytes with age [34].
5.2.1. Cardiovascular diseases and
immunophenotyping changes

Recently Alpert et al. [34] explored a link
between inflammation and cardiovascular disease
using immunoprofiling. This is a powerful example
of the application of immunoprofiling to monitor
chronic diseases that develop with age [34]. For
this study, the authors explored the IMM-AGE
score in the famous Framingham Heart Study
cohort [35] and found that this score was strongly
associated with cardiovascular disease. Therefore,
IMM-AGE score can be used as a risk factor for
the development of cardiovascular disease and
appropriate subjects could therefore be potentially
enrolled in clinical trials based upon their IMMAGE score. Thus, immunoprofiling could serve as
a useful tool in chronic disease prevention studies.
There is a need to expand these studies to other
chronic human diseases as well as in animal
models to confirm their validity.
5.2.2. Age related mortality and
immunophenotyping changes

Aging alters most physiological responses in a
dramatic fashion, including the immune system.

Although age-related changes in DNA methylation
is a good predictor of overall mortality, recent
studies [34] suggest that IMM-AGE score can
predict mortality in older adults better than
epigenetic clock data or chronological age. Using
immunophenotyping the authors found changes in
immune cells from their baseline values over a
9-year period in 135 subjects selected from the
Framingham Heart studies [35]. These studies
suggest that in older adults, the immune systems
change over time and the IMM-AGE score can
predict overall survival independent of age, gender,
and cardiovascular diseases [34].
5.3. Immunophenotyping in cancer therapy

Immune cells are known to infiltrate tumors and
there is good evidence that immunoprofiling can
be used to predict a patient’s anti-tumor response
in cancer therapy [36]. Tumor infiltrating immune
cells represent an important determinant of clinical
responses in immunotherapy. The monitoring of
anti-tumor immune responses by immunoprofiling
during treatment with checkpoint inhibitor drugs
such as anti-CTLA-4 and anti-PD-1 antibodies
has become an essential tool in immunotherapy
[37, 38]. This is important because only about
20%-30% cancer patients respond to checkpoint
immunotherapy [37] and in some cases, it may
even promote tumor growth [39]. Therefore,
immunoprofiling of immune cells may be critical
to determine their efficacy in cancer immunotherapy.
5.4. Immunophenotyping in autoimmune diseases

Autoimmune diseases are caused by the cells of
the immune system. Monitoring and treating
these diseases require a clear understanding of the
type and function of immune cells involved in a
particular disease. Significant progress has been
made to determine the involvement of various
immune cells in autoimmune diseases such as
diabetes, lupus, arthritis, inflammatory bowel
disease and multiple sclerosis [40]. However, the
use of immunotherapy in autoimmune diseases
remains a major challenge in clinical medicine
due to the paucity of effective treatments to
inhibit or regulate autoreactive effector immune
cells in the disease process. Immunoprofiling of
these cells is likely to facilitate development of
new immunotherapies for autoimmune diseases.
The use of biomarkers to define these immune
cells has also become an important diagnostic step
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in the classification and monitoring of the clinical
course of an autoimmune disease [41, 42]. Use of
immunophenotyping to monitor various mononuclear
cell subsets, including memory B cells, effector
T cells, and dendritic cells in autoimmune disease
is likely to become a precision medicine tool in
the diagnosis and follow-up of patients with
autoimmune diseases.
Type 1 diabetes (T1D) is characterized by a change
in the frequency and phenotype of immune cells
during the development of the disease [43]. This
is associated with humoral immune responses to
islet b-cell autoantigens—particularly insulin,
glutamic acid decarboxylase (GAD), islet antigen-2
(IA-2), and zinc transporter 8 (ZnT8). The titer of
autoantibodies to these antigens in T1D increases
with time. The immunophenotyping in this case is
characterized by a more intense humoral autoimmune
response to islet autoantigens. Patients with T1D
also exhibited multiple immunophenotypic
abnormalities in circulating B cells compared to
healthy controls [44]. This is associated with
decreased percentages of Fas receptor- positive
mature B cells. Immunophenotypic analysis has
shown that both CD4 and CD8 T cells are
involved in T1D. These cells are kept in check by
regulatory T (Treg) cells whose diminished Treg
cell function appears to be involved in T1D
development [45, 46]. It is, therefore, going to be
critical to monitor the frequency of Treg cells in
T1D patients using immunoprofiling in patients.
The role of dendritic cells is also important in
T1D as they influence the activation and function
of T cells that are involved in the induction and
progression of disease. In our studies [47],
immunoprofiling of dendritic cells was done using
4-color flow cytometry of whole blood cells from
type 1 and type 2 diabetic patients and control
subjects. It was found that dendritic cell frequency
in the diabetic state did not differ from
nondiabetic control subjects but they were poor
producers of IFN-α which may influence disease
development.
Rheumatoid arthritis (RA) is a chronic autoimmune
disease. In this disease, immunophenotyping has
revealed a link between HLA-DRB1 and CXCR4
expression on memory CD4+ T cells that are
involved in the disease process [48]. In this study,
the authors analyzed HLA-DRB1+ RA patients
by 24-subset immunophenotyping on peripheral

blood mononuclear cells using flow cytometry.
They found that the frequency of memory
CXCR4+CD4+ T cells is linked to the expression
of HLA-DR on B cells. Moreover, memory
CXCR4+CD4+ T cells serves as an important
biomarker for linkage between HLA-DRB1
genotype and disease activity in RA.
Immunophenotyping has also revealed that patients
with systemic lupus erythematosus (SLE or lupus)
can be classified into three subgroups based on
the heterogeneity of T cells involved in the
disease [49]. The level of Treg and follicular
helper T (Tfh) cells were higher in SLE patients
than in healthy controls. Cluster analysis from this
study has shown that patients whose SLE was
resistant to treatment was highest among the Tfhdominant group.
Immunotherapy of multiple sclerosis (MS) has
been monitored by immunoprofiling of immune
cells in patients treated with interferon-β (IFN-β)
and fingolimod. The study revealed significant
alterations in their B cell subsets and an increase
in B cell-activating factor (BAFF) following
therapy [50]. This was unexpected as previous
studies primarily focused on the role of T cells
and not on B cells in MS [51]. Similar results
were obtained in MS patients treated with antiCD20 monoclonal antibodies that targeted B cells
and modulated disease [52].
In Inflammatory Bowel Disease (IBD), a disease
in which gut microbiota plays an important role,
there appears to be a strong link between T cell
subsets and disease induction as determined by
immune profiling of T cells in the intestine [53,
54]. This study explored changes in intestinal
T cells and found increased level of CD4+ T cells,
Tregs, and resident memory T (TRM) cells, and
lower levels of CD8+ T cells and CD103+ T cells
in patients compared to the controls. This suggests
that the baseline level of CD4+ Treg cells in
IBD patients was strongly associated with IBD
progression.
6. Significance of immunoprofiling data in
health and disease management
The immune system impacts almost every disease
in humans and immunophenotyping has potential
to characterize individual’s immune health by
analysing the number of different types of
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immune cells during the course of chronic diseases,
vaccination or cell and organ transplantation.
Healthcare providers can use immunophenotyping
information not only to determine appropriate
patient care, including better timing for clinical
interventions, but also for managing personnel
health and safety (e.g., by designing adequate
vaccination programs for healthcare workers or
other first responders during an infectious disease
outbreak). The study by Alpert et al. [34] suggests
that various clinical studies and drug trials for
chronic and inflammatory diseases could benefit
from the immune profiling studies using the
patients’ peripheral blood cells combined with
genetic biomarkers. Chronic inflammatory immunemediated diseases are a growing health burden
around the globe and are affecting millions of
people. These diseases pose a major challenge to
healthcare providers and to all levels of governments
as they require significant investments for treatment
and prevention. A major research effort is needed
to develop better understanding of the human
immune system to harness the potential of the
immune-mediated therapies and vaccines. The
payoffs are likely to be very significant as is
already evident from the new cancer immunotherapies
where phenotyping of immune cells has become
an essential step in monitoring disease remission.
The human immunoprofiling platforms are likely
to play an important role in both developing new
knowledge of the complex human immune system
and translation of the results into effective
therapies (broad and personalized) to treat various
clinical conditions.
Apart from public policy implications there are
significant ethical challenges that impose a bias
towards the use of experimental systems that
make ex vivo use of human material (either from
healthy volunteers or from patients) on which
manipulations and perturbations can be freely
applied. These concerns will need to be addressed
as we develop powerful new large data sets of
patient immune cells for specific therapy and
for translation of their products for commercial
clinical application.
7. Conclusion
The immune system is a Complex Adaptive
System (CAS) which is strongly influenced by its

ongoing interaction with the environment. Recent
immunoprofiling studies outlined above have
provide fascinating new insight into the human
immune system and its promising role in health
and disease. It is imperative to translate new basic
biomedical research findings relating to the
human immune system into clinical applications
and outcomes. We demonstrated in this review
that immunoprofiling offers an important new
platform for analyzing immune cells in the
evolution of human immunology as it emerges
from the shadows of mouse centric studies [16].
Immunoprofiling studies outlined above point to
the new opportunities that the area of human
immunology research offers to clinical medicine
going forward.
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